UK-based Metrion Biosciences Ltd has appointed Steve Jenkinson, formerly of Pfizer Inc, to lead the expansion of its ion channel drug discovery business in the US. He has been named head of drug discovery and safety assessment. At Pfizer, he was a senior director leading the company’s secondary pharmacology and high throughput screening team. Prior to this, he managed drug discovery projects at Mitsubishi Tanabe Pharma America and GSK Plc. He has also been co-chair of a pharmacology working group at the IQ Consortium. Dr Jenkinson holds a PhD in molecular pharmacology from the University of Leicester, UK, and completed two postdoctoral research fellowships in the US.
Metrion announced the appointment on 12 June 2023.
Copyright 2023 Evernow Publishing Ltd